<DOC>
	<DOCNO>NCT00136513</DOCNO>
	<brief_summary>The purpose study find dose SB-743921 adult patient solid tumor lymphoma progressed standard therapy relapse . SB-743921 dosed 1-hour intravenous infusion every 3 week . A patient may continue receive treatment long benefiting treatment . Blood sample take specific time measure amount drug body specific time drug give . Blood sample also take lab test complete blood count clinical chemistry . Physical exam perform treatment SB-743921 . During treatment phase , patient undergo regular assessment safety clinical response .</brief_summary>
	<brief_title>SB-743921 In Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis : ) Advanced solid tumor malignancy responsive standard therapy standard therapy ; OR b ) Bcell Tcell lymphoma ( exclude HIVassociated lymphoma ) relapse refractory prior chemotherapy radiotherapy autologous allogeneic bone marrow transplantation ( appropriate ) AND/OR salvage chemotherapy , radiotherapy , bone marrow transplantation indicate refused patient . ECOG ( Eastern Cooperative Oncology Group ) Performance Status 02 . Exclusion criterion : Preexisting hemolytic anemia . Preexisting peripheral neuropathy great equal grade 2 . Absolute neutrophil count less 1,500/mm3 . Platelets le 100,000/mm3 . Hemoglobin le 9 g/dL . Total bilirubin great than1.5 mg/dL . AST/ALT great 2.5 X upper limit normal . Creatinine clearance less equal 60 mL/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>dose limit toxicity</keyword>
	<keyword>solid tumor</keyword>
</DOC>